Nelkarmi gives ALK-positive lung cancer patients a new option after first-line therapy stops working

GSK's Nelkarmi (neladalkib) received FDA accelerated approval for ALK-positive NSCLC patients after prior ALK therapy. Approval based on ALKOVE-1 trial showing 49% tumor shrinkage in Alecensa-only group. GSK acquired Nelkarmi via Nuvalent acquisition. Continued approval contingent on confirmatory trial. ALKAZAR phase 3 trial ongoing for first-line treatment.

Original reporting
Published Nov 18, 2026, 9:53 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 10:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Nelkarmi gives ALK-positive lung cancer patients a new option after first-line therapy stops working — source image
Decision brief

The 30-second read

$GSKBullishMed
01

Why it matters

The decision is based on tumor response rates and duration from the ALKOVE-1 single-arm phase 1/2 trial, with pooled safety data and explicit accelerated-approval language that continued approval depends on confirmatory benefit.

02

Market read

Traders can reassess GSK’s oncology pipeline value and near-term sentiment as Nelkarmi moves from trial to label, while also pricing in accelerated-approval confirmatory risk and safety considerations.

03

What to watch

Safety signals (notably liver toxicity) and the accelerated-approval dependency on confirmatory clinical benefit could limit adoption and future label durability, affecting near-term commercialization expectations.

Relevance 7/10Novelty 8/10Timing: post-FDA decision, ahead of ALKAZAR Phase 3 readouts

Background

The FDA granted accelerated approval to Nelkarmi (neladalkib), a once-daily oral ALK-targeted therapy, for adults with locally advanced or metastatic ALK-positive NSCLC after prior ALK-targeted treatment.

Company-level read

Ticker impact

$GSKBullishMedium confidence
Context

GSK said the FDA granted accelerated approval to Nelkarmi (neladalkib) for ALK-positive NSCLC after prior ALK-targeted therapy, adding it to its pipeline.

Expected impact

Likely positive bias as investors price in incremental revenue optionality and validate the Nuvalent acquisition’s clinical progress, tempered by confirmatory-trial risk.

Evidence & confidence

The article is a first-report FDA accelerated approval with efficacy and safety details, plus a planned Phase 3 first-line head-to-head (ALKAZAR), which can support sentiment even though accelerated approvals carry follow-on uncertainty.

Market effects

Reinforces competitive intensity in ALK-positive NSCLC targeted therapy sequencing, with attention on durability and tolerability after prior ALK TKIs.

Primarily US regulatory-driven sentiment for global pharma oncology portfolios.

May influence global ALK-positive NSCLC treatment algorithms and payer discussions internationally as the confirmatory evidence path becomes clearer.

Counterpoint

Because this is accelerated approval, the market may overreact to response rates while underweighting the probability and timeline of confirmatory trial success.

Key entities

  • Nelkarmi (neladalkib)

    Once-daily oral ALK-targeted therapy receiving FDA accelerated approval for previously treated ALK-positive NSCLC.

  • GSK

    Sponsor that announced the FDA accelerated approval and links Nelkarmi to its Nuvalent acquisition pipeline.

  • ALKOVE-1

    Single-arm phase 1/2 trial used to support the accelerated approval decision.

  • ALKAZAR

    Phase 3 trial comparing Nelkarmi versus Alecensa in previously untreated ALK-positive NSCLC.

  • Alecensa (alectinib)

    Current standard ALK TKI referenced as the comparator and as the only prior ALK TKI subgroup.

Related articles

$GSKMedAI 8/10

GSK’s $10.6bn Nuvalent bet pays off with second lung cancer drug approval

GSK's Nelkarmi (neladalkib) received FDA approval for treating ALK-positive non-small cell lung cancer, the second drug from its $10.6bn Nuvalent acquisition. The approval was based on trial results showing a 49% response rate. GSK expects significant sales, with forecasts predicting $1.2bn by 2032. Roche's Alecensa is a key competitor. Approval hinges on ongoing Phase III trial results.

$GSKMed

GSK Wins Second Lung Cancer Approval of 2026 as FDA Clears Nelkarmi — BigGo Finance

GSK (GSK) received FDA approval for Nelkarmi, a lung cancer drug, based on Phase 1/2 trial data. The drug targets ALK gene mutations and showed activity against brain metastases. GSK acquired Nelkarmi through its $10.6B Nuvalent deal. Analysts project $1B in 2032 sales, with peak sales estimates of $5B-$7B for GSK's lead Nuvalent drugs. The approval is seen as a validation of GSK's oncology portfolio strategy.

$SMMTMedAI 8/10

FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK

FDA rejected Summit Therapeutics' ivonescimab for lung cancer, citing insufficient benefits. Sellas Life Sciences' cancer vaccine showed 41% reduced death risk in a Phase 3 trial. GSK's Nelkarmi, acquired via Nuvalent buyout, gained FDA approval for lung cancer. AstraZeneca's gefurulimab was approved for myasthenia gravis. Eli Lilly partnered with Stipple Bio for cancer drugs, potentially worth $5.9B. Biogen invested $32M in Trimtech for neurodegenerative disease treatments.

$GSKMed

GSK gets second cancer drug approval from Nuvalent buy

GSK's Nelkarmi (neladalkib) received FDA approval for ALK-positive NSCLC after prior ALK inhibitor treatments. The approval follows GSK's $10.6B acquisition of Nuvalent. Analysts project Nelkarmi, Jideytro, and NVL-330 could generate $5B-$7B in annual sales. Nelkarmi showed a 49% objective response rate in trials. GSK aims to boost revenues to £40B by 2031.

$GSKMed

GSK wins early FDA approval for lung cancer drug Nelkarmi

GSK received early FDA approval for its lung cancer drug Nelkarmi, based on trial data showing meaningful responses in patients with prior ALK inhibitor therapies. The drug demonstrated a 49% response rate in patients with one prior treatment and 32% in those with multiple treatments. GSK noted the approval strengthens its oncology portfolio and addresses unmet needs in ALK-positive lung cancer. As of 1010 GMT, GSK shares were down 0.08% at 1,867.50p.